Sobi publishes Q2 2023 report: Growth and pipeline expansion

18 Jul 2023
www.prnewswire.com
AcquisitionDrug ApprovalFinancial StatementBiosimilar
STOCKHOLM, July 18, 2023 /PRNewswire/ --
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2023
Second quarter 2023
Total revenue increased 26 per cent, +16 per cent at constant exchange rates, (CER)i, to SEK 4,872 M (3,876)
Haematology revenue increased 18 per cent at CER to SEK 3,430 M (2,688). Driven by Doptelet® +74 per cent at CER and the launch of Aspaveli®/Empaveli® SEK 144 M
Immunology revenue increased 29 per cent at CER to SEK 1,179 M (847). Driven by Gamifant® +73 per cent at CER and Kineret® +12 per cent at CER
Adjusted EBITAi margin expanded by 1 percentage point to 26 per cent, excluding transaction costs and other items affecting comparability (IAC)ii. EBITA at SEK 1,009 M (944), a margini of 21 per cent (24). EBIT SEK 413 M (423), EBIT adjustedi SEK 649 M (437)
Earnings per share (EPS) before dilution SEK 0.75 (0.87), EPS adjusted before dilutioni SEK 1.48 (0.91). Cash flow from operating activities SEK 357 M (295)
The acquisition of CTI BioPharma Corp. (CTI) was completed
After the end of the quarter, the FDA approved Sanofi and AstraZeneca's Beyfortus™ (nirsevimab-alip) for the prevention of RSV in babies and toddlers
The Board has today summoned an extraordinary general meeting, to be held on 15 August 2023, to resolve on, among other things, an authorisation for the Board of Directors to resolve on a rights issue of approximately SEK 6 billion, to refinance part of the debt incurred in connection with the acquisition of CTI
Outlook 2023 - updated
Revenue is anticipated to grow by a high single-digit percentage at CER (previous guidance low-to-mid single digit)
EBITA margin adjustedi is anticipated to be at a low 30s percentage of revenue (unchanged)
The outlook includes the newly acquired company CTI and Sobi's right to royalty on net sales of nirsevimab in the US.
Investors, analysts and media are invited to participate in a conference call which will include a presentation of the results and a Q&A session at 13:00 CEST.
The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com prior to the conference call.
To participate in the conference call, please use the following dial-in details:
Sweden: +46 8 5051 0031
United Kingdom: +44 207 107 06 13
United States: +1 631 570 56 13
For other countries, please get details here
Footnotes:
i  Excluding IAC.
ii  Alternative Performance Measures (APMs), see section APM for further information.
iii Items affecting comparability (IAC), see page 3 for further information.
Sobi
SobiSobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East, Asia and Australia. In 2022, revenue amounted to SEK 18.8 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.
Contact:
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, on 18 July 2023 at 08:00 CEST.
Jennifer Kretzmann
Manager of Stakeholder Communication and Corporate Access
The following files are available for download:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.